194 related articles for article (PubMed ID: 29864460)
1. Improving the performance of virtual crossmatch results by correlating with nationally-performed physical crossmatches: Obtaining additional value from proficiency testing activities.
Wrenn SM; Marroquin CE; Hain DS; Harm SK; Pineda JA; Hammond PB; Shah DH; Hillyard SE; Fung MK
Hum Immunol; 2018 Aug; 79(8):602-609. PubMed ID: 29864460
[TBL] [Abstract][Full Text] [Related]
2. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of solid phase HLA antibody assays for prediction of crossmatch strength.
Ellis TM; Schiller JJ; Roza AM; Cronin DC; Shames BD; Johnson CP
Hum Immunol; 2012 Jul; 73(7):706-10. PubMed ID: 22537747
[TBL] [Abstract][Full Text] [Related]
4. Donor-specific HLA antibodies in predicting crossmatch outcome: Comparison of three different laboratory techniques.
Peräsaari JP; Jaatinen T; Merenmies J
Transpl Immunol; 2018 Feb; 46():23-28. PubMed ID: 29157597
[TBL] [Abstract][Full Text] [Related]
5. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
[TBL] [Abstract][Full Text] [Related]
7. Sensitization and sensitivity: defining the unsensitized patient.
Gebel HM; Bray RA
Transplantation; 2000 Apr; 69(7):1370-4. PubMed ID: 10798756
[TBL] [Abstract][Full Text] [Related]
8. Antihuman leukocyte antigen–specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches.
Batal I; Zeevi A; Lunz JG; Aggarwal N; Shapiro R; Randhawa P; Girnita A
Arch Pathol Lab Med; 2010 Oct; 134(10):1534-40. PubMed ID: 20923311
[TBL] [Abstract][Full Text] [Related]
9. Multilaboratory evaluation of serum analysis for HLA antibody and crossmatch reactivity by lymphocytotoxicity methods.
Duquesnoy RJ; Marrari M
Arch Pathol Lab Med; 2003 Feb; 127(2):149-56. PubMed ID: 12562227
[TBL] [Abstract][Full Text] [Related]
10. Center-defined unacceptable HLA antigens facilitate transplants for sensitized patients in a multi-center kidney exchange program.
Baxter-Lowe LA; Cecka M; Kamoun M; Sinacore J; Melcher ML
Am J Transplant; 2014 Jul; 14(7):1592-8. PubMed ID: 24934640
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Rapid Optimized 96-well Tray Flow Cytometric Crossmatch (Halifax-FCXM) with Luminex Single Antigen Test.
Yoo J; Lee S; Lee HW; Lee S; Choi J; Han J; Kang H; Choi A; Hee Jang J; Oh EJ
Hum Immunol; 2021 Apr; 82(4):302-308. PubMed ID: 33744026
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of Luminex-based donor-specific antibody mean fluorescence intensity values with complement-dependent cytotoxicity & flow crossmatch results in live donor renal transplantation.
Baranwal AK; Bhat DK; Goswami S; Agarwal SK; Kaur G; Kaur J; Mehra N
Indian J Med Res; 2017 Feb; 145(2):222-228. PubMed ID: 28639599
[TBL] [Abstract][Full Text] [Related]
13. Kidney transplantation with positive complement-dependent lymphocytotoxicity crossmatch with negative flow crossmatching and Luminexx donor-specific antibodies.
Kute VB; Vanikar AV; Gumber MR; Trivedi VB; Shah PR; Patel HV; Balwani MR; Modi PR; Trivedi HL
Ren Fail; 2013 Aug; 35(7):1027-30. PubMed ID: 23829775
[TBL] [Abstract][Full Text] [Related]
14. Improved detection of donor-specific HLA-class II antibody in kidney transplant recipients by modified immunocomplex capture fluorescence analysis.
Shimabukuro S; Iwasaki K; Kawai S; Shirouzu T; Miwa Y; Iida Y; Nakajima F; Horimi K; Matsuoka Y; Ashimine S; Ishiyama K; Kobayashi T
Transpl Immunol; 2021 Aug; 67():101418. PubMed ID: 34052300
[TBL] [Abstract][Full Text] [Related]
15. Reducing number of laboratories performing complement dependent cytotoxicity crossmatching: Reasons and conclusions.
Putheti P; Liwski RS; Jindra PT
Hum Immunol; 2022 May; 83(5):467-475. PubMed ID: 35183390
[TBL] [Abstract][Full Text] [Related]
16. Complement-dependent cytotoxicity crossmatch in solid organ transplantation: The gold standard or golden history?
Tafulo S; Osório E; Mendes C; Liwski R
Hum Immunol; 2024 Jan; 85(1):110734. PubMed ID: 38030522
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of complement-dependent lymphocytotoxicity crossmatch and flow cytometry crossmatch results versus Luminex single-antigen bead-based donor-specific IgG class I antibody MFI values in live related renal transplant cases; a retrospective observation in 102 cases.
Pandey P; Pande A; Kumar Devra A; Kumar Sinha V; Prasad Bhatt A
J Immunoassay Immunochem; 2021 May; 42(3):300-313. PubMed ID: 33356865
[TBL] [Abstract][Full Text] [Related]
18. Development of data-driven models for the flow cytometric crossmatch.
Weimer ET; Newhall KA
Hum Immunol; 2019 Dec; 80(12):983-989. PubMed ID: 31530432
[TBL] [Abstract][Full Text] [Related]
19. Reassessment of T Lymphocytes Crossmatches Results Prediction With Luminex Class I Single Antigen Flow Beads Assay.
Visentin J; Bachelet T; Borg C; Franchini N; Nong T; Lee JH; Couzi L; Merville P; Guidicelli G; Taupin JL
Transplantation; 2017 Mar; 101(3):624-630. PubMed ID: 27336398
[TBL] [Abstract][Full Text] [Related]
20. Combined liver-kidney transplantation with positive crossmatch: Role of delayed kidney transplantation.
Goggins WC; Ekser B; Rokop Z; Lutz AJ; Mihaylov P; Mangus RS; Fridell JA; Powelson JA; Kubal CA
Surgery; 2021 Oct; 170(4):1240-1247. PubMed ID: 34092375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
